Telomir Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
TELO$0.69-2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements
Our Financial Statements and Notes thereto and the reports of Salberg & Company P.A, our independent registered public accounting firm, for the years ended December 31, 2025 and 2024, are set forth on pages F-1 through F-16 of this Report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.